Medpace Holdings (MEDP) Cash & Equivalents (2015 - 2026)

Medpace Holdings (MEDP) has 12 years of Cash & Equivalents data on file, last reported at $502.7 million in Q2 2026.

• Quarterly Cash & Equivalents rose 985.02% year-over-year to $502.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $502.7 million (up 985.02% YoY) and the FY2025 annual result came in at $497.0 million, down 25.75% from the prior year.
• Cash & Equivalents slipped to $502.7 million in Q2 2026, from $652.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $669.4 million in Q4 2024 to a low of $28.3 million in Q4 2022.
• A 5-year average of $293.4 million and a median of $265.4 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 93.87% — and 2024, when it jumped 1205.37%.
• Tracing MEDP's Cash & Equivalents over 5 years: stood at $28.3 million in 2022, then jumped by 768.38% to $245.4 million in 2023, then jumped by 172.74% to $669.4 million in 2024, then dropped by 25.75% to $497.0 million in 2025, then advanced by 1.13% to $502.7 million in 2026.
• The last three Cash & Equivalents figures came in at $502.7 million (Q2 2026), $652.7 million (Q1 2026), and $497.0 million (Q4 2025), per Business Quant data.